AdoRx rais­es $10M for adeno­sine pro­gram in can­cer; Mol­e­c­u­lar Part­ners poach­es Re­gen­eron, re­cruit­ing Pamela Trail as CSO

→ A day af­ter iTeos raised $75 mil­lion to ac­cel­er­ate its re­search plans on an adeno­sine pro­gram for can­cer, a new ri­val has sprung up in Scot­land. AdoRx has raised $10 mil­lion from Ep­i­darex Cap­i­tal and CRT Pi­o­neer Fund, af­ter get­ting some seed cash to­geth­er for a launch last year. CEO Pe­ter Fi­nan is a part­ner at Ep­i­darex and has se­nior-lev­el ex­pe­ri­ence han­dling re­search at the No­var­tis In­sti­tutes for Bio­Med­ical Re­search. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER